AI Terminal
ABIVAX
Report Publication Announcement • Nov 2, 2020
1063_rns_2020-11-02_47e5f9df-35d0-4c41-8a4e-6b401d5ae97e.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
News Details
Corporate | 2 November 2020 14:00
Abivax announces webcast and teleconference following recent oversubscribed capital increase of EUR 28m at market price
DGAP-News: ABIVAX / Key word(s): Miscellaneous
02.11.2020 / 14:00
The issuer is solely responsible for the content of this announcement.
Abivax announces webcast and teleconference following recent oversubscribed capital increase of EUR 28m at market price
PARIS, November 02, 2020 – 2:00 p.m. (CET) – Abivax (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces that its senior management will host a webcast and teleconference on Tuesday, November 3, 2020 at 3:00 pm CET (Paris time), to discuss the recently announced oversubscribed capital increase of EUR 28m at market price, company developments as well as address questions.
Attendees can participate by weblink ( https://channel.royalcast.com/webcast/abivaxwebcast/20201103_1/ ) or connect by phone using the following telephone numbers.
Dial in details for participants:
France: +33 (0) 1 7037 7166
UK (Standard International Access): +44 (0) 20 3003 2666
U.S.: +1 212 999 6659
Belgium: +32 (0) 2 789 8603
Password: abivax
About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment C (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.
More information on the company is available at www.abivax.com . Follow us on Twitter @ABIVAX_.
Contacts
| Abivax Communications Regina Jehle [email protected] +33 6 24 50 69 63 |
Investors LifeSci Advisors Chris Maggos [email protected] +41 79 367 6254 |
Press Relations & Investors Europe MC Services AG Anne Hennecke [email protected] +49 211 529 252 22 |
| Public Relations France Actifin Ghislaine Gasparetto [email protected] +33 6 21 10 49 24 |
Public Relations France DGM Conseil Thomas Roborel de Climens [email protected] +33 6 14 50 15 84 |
Public Relations USA Rooney Partners LLC Marion Janic [email protected] +1 212 223 4017 |
02.11.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de